
Alzprotect Reports Positive Results from Phase 2a PSP Study Extension
Alzprotect, a French biopharma company, has successfully completed the open-label extension (OLE) phase of its Phase 2a trial for AZP2006 (ezeprogind®) in treating Progressive Supranuclear Palsy (PSP). Results from the 6-month extension highlight AZP2006’s potential to stabilize or slow disease…












